Animal study on transplantation of human umbilical vein endothelial cells for corneal endothelial decompensation
10.3980/j.issn.1672-5123.2014.06.07
- VernacularTitle:人脐静脉内皮细胞移植治疗角膜内皮功能衰竭的动物实验研究
- Author:
Li, CUI
;
Xiang, MA
;
Yan-Hui, ZHAO
- Publication Type:Journal Article
- Keywords:
human umbilical vein endothelial cell;
acellular corneal stroma;
posterior lamellar endothelial keratoplasty
- From:
International Eye Science
2014;(6):1009-1012
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To explore the feasibility of culturing human umbilical vein endothelial cells ( HUVEC ) on acellular corneal stroma and performing the posterior lamellar endothelial keratoplasty ( PLEK ) treating corneal endothelial decompensation.
METHODS: Thirty New-Zealand rabbits were divided into three groups randomly, 10 rabbits for experimental group, 10 for stroma group and 10 for control group. Corneal endothelial cells were removed to establish animal model of corneal endothelial failure. PLEK was performed on the rabbits of experimental group and stroma group, and nothing was transplantated onto the rabbits of control group with the deep layer excised only. Postoperative observation was taken for 3mo. The degree of corneal edema and central corneal thickness were recorded for statistical analysis.
RESULTS:Corneas in experimental group were relieved in edema obviously compared with that in stroma group and the control group, and showed increased transparency 7d after the operation. The average density of endothelial cells was 2 026. 4±129. 3cells/mm2 , and average central corneal thickness was 505. 2±25. 4μm in experimental group, while 1 535. 6±114. 5μm in stroma group and 1 493. 5±70. 2μm in control group 3mo after operation.
CONCLUSION:We achieved preliminary success in our study that culturing HUVEC on acellular corneal stroma and performing PLEK for corneal endothelial decompensation. HUVEC transplanted could survive in vivo, and have normal biological function of keeping cornea transparent. This study provides a new idea and a new way clinically for the treatment of corneal endothelial diseases.
